GlaxoSmithKline PLC Director/PDMR Shareholding (1940F)
16 Febbraio 2018 - 6:25PM
UK Regulatory
TIDMGSK
RNS Number : 1940F
GlaxoSmithKline PLC
16 February 2018
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
This notification sets out the vesting details of awards over
Ordinary Shares and American Depositary Shares ('ADS') made in 2015
under the GlaxoSmithKline Performance Share Plan ('PSP'), which
were subject to relevant business performance conditions. The
three-year performance period for the 2015 awards commenced on 1
January 2015 and ended on 31 December 2017.
The performance measure vesting details for those Persons
Discharging Managerial Responsibilities ('PDMRs') who received
awards in 2015 are set out in the following table.
Outcome and
Vesting Level
----------------------------------------------- ------------------
Portion Measure and Outcome % of % of
of the maximum award
Award
--------- ------------------------------------ --------- -------
Adjusted Free Cash Flow -
For the three-year period,
the Company achieved Adjusted
Free Cash Flow calculated
in accordance with the principles
for the measure of GBP12.47bn
which is above the threshold
1/3(rd) level of GBP11.48bn. 63 21
--------- ------------------------------------ --------- -------
Total Shareholder Return
- For the three years ending
31 December 2017, the Company's
Total Shareholder Return
ranked 5(th) , which is above
the threshold vesting level
against a comparator group
of 10 global pharmaceutical
1/3(rd) companies including GSK. 44 14.67
--------- ------------------------------------ --------- -------
R&D New Products - For the
three-year period, the Company
achieved New Product sales
calculated in accordance
with the principles for the
measure of GBP11.266bn, which
is above the maximum vesting
level of GBP7.912bn (the
1/3(rd) threshold level was GBP6.474bn). 100 33.33
--------- ------------------------------------ --------- -------
Total vesting for 2015 award 69%
Lapsed 31%
--------------------------------------------------------- -------
The notifications that follow are for awards made to PDMRs and
detail the PSP conditional awards that vested, including dividends
accrued, on 15 February 2018. The balance of the award made to each
PDMR has lapsed.
The closing share prices of an Ordinary Share and of an ADS of
GlaxoSmithKline plc at the point of vesting on 15 February 2018
were GBP13.004 and $37.31.
Transaction notification
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Ms E Walmsley
=== ====================== ================================
b) Position/status Chief Executive Officer
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== ================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 91,430
---------- ----------
GBP0.00 47,391
---------- ----------
=== ====================== ================================
d) Aggregated
information 138,821
Aggregated GBP0.00
volume Price
=== ====================== ================================
e) Date of the 2018-02-15
transaction
=== ====================== ================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Mr R Connor
=== ====================== ================================
b) Position/status President, Global Manufacturing
& Supply
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== ================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 71,160
---------- ----------
=== ====================== ================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ================================
e) Date of the 2018-02-15
transaction
=== ====================== ================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =========================================================
a) Name Mr L Debruyne
=== ====================== =================================
b) Position/status President, Global Vaccines
=== ====================== =================================
c) Initial notification/ Initial notification
amendment
=== ====================== =================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =========================================================
a) Name GlaxoSmithKline plc
=== ====================== =================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== =================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== =================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== =================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 18,203
---------- ----------
=== ====================== =================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== =================================
e) Date of the 2018-02-15
transaction
=== ====================== =================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== =================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ==========================================================
a) Name Mr S Dingemans
=== ====================== ==================================
b) Position/status Chief Financial Officer
=== ====================== ==================================
c) Initial notification/ Initial notification
amendment
=== ====================== ==================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ==========================================================
a) Name GlaxoSmithKline plc
=== ====================== ==================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan. These
shares are subject to a two-year
holding period to end in 2020.
=== ====================== ==================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 154,763
---------- ----------
=== ====================== ==================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==================================
e) Date of the 2018-02-15
transaction
=== ====================== ==================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ==================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =========================================================
a) Name Mr N Hirons
=== ====================== =================================
b) Position/status SVP, Global Ethics and Compliance
=== ====================== =================================
c) Initial notification/ Initial notification
amendment
=== ====================== =================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =========================================================
a) Name GlaxoSmithKline plc
=== ====================== =================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== =================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== =================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== =================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 34,502
---------- ----------
=== ====================== =================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== =================================
e) Date of the 2018-02-15
transaction
=== ====================== =================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== =================================
1. Details of PDMR/person closely associated
with them ('PCA')
==== ==============================================================
a) Name Mr B McNamara
==== ======================= =====================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================= =====================================
c) Initial notification/ Initial notification
amendment
==== ======================= =====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== ==============================================================
a) Name GlaxoSmithKline plc
==== ======================= =====================================
b) LEI 5493000HZTVUYLO1D793
==== ======================= =====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================
a) Description GlaxoSmithKline plc American
of the financial Depositary Shares ('ADSs')
instrument ISIN: US37733W1053
==== ======================= =====================================
b) Nature of The number of ADSs vesting on
the transaction awards granted in 2015 under
the Company's 2009 Performance
Share Plan and which were made
to compensate for the value of
awards forfeited on completion
of the Joint Venture with Novartis.
==== ======================= =====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$0.00 24,345
--------- ----------
$0.00 4,871
--------- ----------
==== ======================= =====================================
Aggregated
d) information
Aggregated
volume Price 29,216
$0.00
============================ =====================================
e) Date of the 2018-02-15
transaction
==== ======================= =====================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================= =====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Mr D Redfern
=== ====================== ================================
b) Position/status Chief Strategy Officer
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== ================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 56,605
---------- ----------
=== ====================== ================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ================================
e) Date of the 2018-02-15
transaction
=== ====================== ================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Ms C Thomas
=== ====================== ================================
b) Position/status SVP, Human Resources
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== ================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 75,473
---------- ----------
=== ====================== ================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ================================
e) Date of the 2018-02-15
transaction
=== ====================== ================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =========================================================
a) Name Mr P Thomson
=== ====================== =================================
b) Position/status President, Global Affairs
=== ====================== =================================
c) Initial notification/ Initial notification
amendment
=== ====================== =================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =========================================================
a) Name GlaxoSmithKline plc
=== ====================== =================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== =================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== =================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== =================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 43,667
---------- ----------
=== ====================== =================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== =================================
e) Date of the 2018-02-15
transaction
=== ====================== =================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== =================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Mr D Troy
=== ====================== ================================
b) Position/status SVP & General Counsel
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description GlaxoSmithKline plc American
of the financial Depositary Shares ('ADSs')
instrument ISIN: US37733W1053
=== ====================== ================================
b) Nature of The number of ADSs vesting on
the transaction awards granted in 2015 under
the Company's 2009 Performance
Share Plan.
=== ====================== ================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$0.00 66,334
--------- ----------
=== ====================== ================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ================================
e) Date of the 2018-02-15
transaction
=== ====================== ================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =========================================================
a) Name Dr P Vallance
=== ====================== =================================
b) Position/status Outgoing President, R&D
=== ====================== =================================
c) Initial notification/ Initial notification
amendment
=== ====================== =================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =========================================================
a) Name GlaxoSmithKline plc
=== ====================== =================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== =================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================
a) Description Ordinary Shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== =================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== =================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 156,984
---------- ----------
=== ====================== =================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== =================================
e) Date of the 2018-02-15
transaction
=== ====================== =================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== =================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =========================================================
a) Name Mrs V Whyte
=== ====================== =================================
b) Position/status Company Secretary
=== ====================== =================================
c) Initial notification/ Initial notification
amendment
=== ====================== =================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =========================================================
a) Name GlaxoSmithKline plc
=== ====================== =================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== =================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================
a) Description Ordinary shares of 25 pence each
of the financial 'Ordinary Shares'
instrument ISIN: GB0009252882
=== ====================== =================================
b) Nature of The number of Ordinary Shares
the transaction vesting on awards granted in
2015 under the Company's 2009
Performance Share Plan.
=== ====================== =================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP0.00 9,667
---------- ----------
=== ====================== =================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== =================================
e) Date of the 2018-02-15
transaction
=== ====================== =================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== =================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDQLFFVLFLBBX
(END) Dow Jones Newswires
February 16, 2018 12:25 ET (17:25 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
